Trivikram Rajkhowa
Overview
Explore the profile of Trivikram Rajkhowa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
991
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Levis M, Perl A, Schiller G, Fathi A, Roboz G, Wang E, et al.
Blood Adv
. 2024 Mar;
8(10):2527-2535.
PMID: 38502195
FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by...
2.
Karantanos T, Teodorescu P, Arvanitis M, Perkins B, Jain T, DeZern A, et al.
Haematologica
. 2022 Dec;
108(7):1886-1899.
PMID: 36519323
Better understanding of the biology of resistance to DNA methyltransferase (DNMT) inhibitors is required to identify therapies that can improve their efficacy for patients with high-risk myelodysplastic syndrome (MDS). CCRL2...
3.
Pratz K, Kaplan J, Levy M, Bixby D, Burke P, Erba H, et al.
Haematologica
. 2022 Oct;
108(3):705-716.
PMID: 36226495
Mivavotinib (TAK-659) is an investigational type 1 tyrosine kinase inhibitor with dual activity against spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). We conducted a phase Ib study...
4.
Karantanos T, Teodorescu P, Perkins B, Christodoulou I, Esteb C, Varadhan R, et al.
Sci Adv
. 2022 Feb;
8(7):eabl8952.
PMID: 35179961
The identification of new pathways supporting the myelodysplastic syndrome (MDS) primitive cells growth is required to develop targeted therapies. Within myeloid malignancies, men have worse outcomes than women, suggesting male...
5.
Lee L, Hizukuri Y, Severson P, Powell B, Zhang C, Ma Y, et al.
Haematologica
. 2021 Jan;
106(4):1022-1033.
PMID: 33504139
Acute myeloid leukemia patients with FLT3-ITD mutations have a high risk of relapse and death. FLT3 tyrosine kinase inhibitors improve overall survival, but their efficacy is limited and most patients...
6.
Maziarz R, Levis M, Patnaik M, Scott B, Mohan S, Deol A, et al.
Bone Marrow Transplant
. 2020 Dec;
56(5):1180-1189.
PMID: 33288862
We evaluated standard-of-care (SOC) treatment with or without midostaurin to prevent relapse following allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with acute myeloid leukemia (AML) harboring internal tandem duplication...
7.
Lee L, Hernandez D, Rajkhowa T, Smith S, Raman J, Nguyen B, et al.
Blood
. 2016 Dec;
129(2):257-260.
PMID: 27908881
No abstract available.
8.
Taub M, Garimella S, Kim D, Rajkhowa T, Cutuli F
Cell Signal
. 2015 Oct;
27(12):2568-78.
PMID: 26432356
Sodium reabsorption by the kidney is regulated by locally produced natriuretic and anti-natriuretic factors, including dopamine and norepinephrine, respectively. Previous studies indicated that signaling events initiated by these natriuretic and...
9.
Strati P, Kantarjian H, Ravandi F, Nazha A, Borthakur G, Daver N, et al.
Am J Hematol
. 2014 Dec;
90(4):276-81.
PMID: 25530214
We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m(-2) on days...
10.
Chen Y, Li S, Lane A, Connolly C, Del Rio C, Valles B, et al.
Biol Blood Marrow Transplant
. 2014 Sep;
20(12):2042-8.
PMID: 25239228
The fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation is associated with a high relapse rate for patients with acute myeloid leukemia (AML) even after allogeneic hematopoietic stem cell...